Unfortunately, the PPAR-α/γ agonist had been reported to increase about 2–4% of body weight and had adverse reactions including peripheral oedema in probably 5% of treated patients and fatal heart failure in approximately 11% of treated patients [40]. The gene discussed is PPARA; the disease is heart failure.